On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Regulatory
-
-
Fujifilm Kyowa Kirin Biologics announced that its Medical Marketing Application (“MMA”) for FKB327, a biosimilar to AbbVie’s Humira®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA announced yesterday that the Oncologic Drug Advisory Committee (“ODAC”) has scheduled a public meeting to review ABP 215,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion announced last week that it has submitted an application for approval of Herzuma, its proposed trastuzumab biosimilar (CT-P6), in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
FDA approved Samsung Bioepis’s Renflexis® (SB2, infliximab-abda) on Friday, April 21, 2017. Renflexis® is the fifth biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Amgen’s Amgevita, an adalimumab biosimilar to AbbVie’s Humira®, received approval from the European Commission on March 23, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion’s Truxima (CT-P10, rituximab), a biosimilar to Rituxan® received approval from the European Commission on February 22, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA has accepted for review an application submitted by Mylan N.V. (“Mylan”) and Biocon Ltd. (“Biocon”) under the 351(k)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]